Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 29, 2021

Primary Completion Date

August 1, 2026

Study Completion Date

February 1, 2028

Conditions
Thrombosis, Deep VeinIliofemoral; Thrombosis
Interventions
COMBINATION_PRODUCT

Perivascular dexamethasone

Dexamethasone delivery around target vein segment(s)

COMBINATION_PRODUCT

Perivascular sham

Saline delivery around target vein segment(s)

Trial Locations (17)

11794

RECRUITING

Stony Brook University Hospital, Stony Brook

15212

RECRUITING

Allegheny General Hospital, Pittsburgh

20782

RECRUITING

Medstar Health Research Institute, Hyattsville

23452

RECRUITING

Sentara Norfolk General Hospital, Norfolk

27607

RECRUITING

NC Heart and Vascular Research, Raleigh

30309

RECRUITING

Piedmont Heart Institute, Atlanta

32258

RECRUITING

Baptist Health, Jacksonville

33060

RECRUITING

University of South Florida, Tampa

33462

RECRUITING

HCA Florida JFK Hospital, Atlantis

43214

ACTIVE_NOT_RECRUITING

OhioHealth Research Institute, Columbus

70360

RECRUITING

CIS Clinical Research, Houma

74006

ACTIVE_NOT_RECRUITING

St John Health System, Bartlesville

92868

RECRUITING

Providence St. Joseph Hospital, Orange

06820

RECRUITING

Vascular Care Connecticut, Darien

07631

RECRUITING

Englewood Health, Englewood

H91 YR71

COMPLETED

Galway University Hospital, Galway

SE1 7EH

ACTIVE_NOT_RECRUITING

Guy's and St. Thomas Hospital, London

Sponsors
All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Mercator MedSystems, Inc.

INDUSTRY

NCT04862468 - Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT | Biotech Hunter | Biotech Hunter